HC Wainwright Comments on Kiora Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – HC Wainwright cut their Q2 2024 earnings estimates for Kiora Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2024 earnings at $0.15 EPS.

Kiora Pharmaceuticals Stock Down 2.7 %

Shares of Kiora Pharmaceuticals stock opened at $0.56 on Wednesday. Kiora Pharmaceuticals has a twelve month low of $0.45 and a twelve month high of $2.24. The company has a fifty day moving average price of $0.56 and a 200 day moving average price of $0.58.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals accounts for about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 22nd largest position. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.